Oral treatment of visceral leishmaniasis with miltefosine

Annals of Tropical Medicine and Parasitology

Volumn 93, Issue 6, 1999, Pages 589-597

  Sundar, S ^a   Gupta, L B ^a   Makharia, M K ^a   Singh, M K ^a   Voss, A ^b   Rosenkaimer, F ^b   Engel, J ^b   Murray, H W ^c  

^a BANARAS HINDU UNIVERSITY   (India)

^b ASTA MEDICA AG   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ASPARTATE AMINOTRANSFERASE; CREATININE; MILTEFOSINE; NITROGEN;

ADOLESCENT; ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; FEMALE; HUMAN; LIVER TOXICITY; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; VOMITING;

PROTOZOA;

EID: 0032862788     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1080/00034983.1999.11813462     Document Type: Article

References (16)

1. ANON. (1995). Miltex (INN Miltefosine): Investigator's Brochure. Frankfurt: ASTA Medica.
2. BERMAN, J. D. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases, 24, 684-703.
3. CROFT, S. L., SNOWDON, D. & YARDLEY, V. (1996). The activities of four anticancer alkyllsophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Journal of Antimicrobial Chemotherapy, 38, 1041-1047.
4. DANHAUSER-RIEDL, S., DROZD, A., ZAFFERANI, M., BRUNTSCH, U., PEUKERT, M., SINDERMANN, H., PRAUER, H. W., SIEWERT, J. R., RASTETTER, J. & BERDEL, W. E. (1991). Phase I study of weekly oral miltefosine (hexadecyl-phosphocholine) in cancer patients. Onkologie, 14, 392-400.
5. JHA, T. K., OLLIARO, P., THAKUR, C. P., KANYOK, T. P., SINGHANIA, B. L., SINGH, I. J., SINGH, N. K. P., AKHOURY, S. & JHA, S. (1998). Randomized controlled trial of aminosidine (paramomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. British Medical Journal, ii, 1200-1205.
6. KUHLENCORD, A., MANIERA, T., EIBL, H. & UNGER, C. (1992). Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrobial Agents and Chemotherapy, 36, 1630-1634.
7. LE FICHOUX, Y., ROUSSEAU, D., FERRUA, B., RUETTE, S., LELIEVRE, A., GROUSSON, D. & KUBAR, J. (1998). Short and long term efficacy of hexadecylphosphocholine in established Leishmania infantum infection in BALB/c mice. Antimicrobial Agents and Chemotherapy, 42, 654-658.
8. OLLIARO, P. L. & BRYCESON, A. D. M. (1993). Practical progress and new drugs for changing patterns of leishmaniasis. Parasitology Today, 9, 323-328.
9. PEARSON, R. D. & DE QUEIROZ SOUSA, A. (1996). Clinical spectrum of leishmaniasis. Clinical Infectious Diseases, 22, 1-13.
10. PRONK, L. C., PLANTING, A. S. T., OOSTEROM, R., DROGENDIJK, T. E., STOTER, G. & VERWEIJ, J. (1994). Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. European Journal of Cancer, 30A, 1019-1022.
11. SUNDAR, S., ROSENKAIMER, F., LESSER, M. & MURRAY, H. W. (1995). Immunochemotherapy for an intracellular infection: accelerated response using IFN-γ in visceral leishmaniasis. Journal of Infectious Diseases, 171, 992-996.
12. SUNDAR, S., AGRAWAL, N. K., SINHA, P. R., HORWITH, G. S. & MURRAY, H. W. (1997a). Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine, 127, 133-137.
13. SUNDAR, S., SINGH, V. P., SHARMA, S., MAKHARIA, M. K. & MURRAY, H. W. (1997b). Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases, 176, 1117-1119.
14. SUNDAR, S., ROSENKAIMER, F., MAKHARIA, M. K., GOYAL, A. K., MANDAL, A. K., VOSS, A. & MURRAY, H. W. (1998). Trial of miltefosine for visceral leishmaniasis. Lancet, ii, 1821-1823.
15. THAKUR, C. P., SINHA, G. P., PANDEY, A. K., KUMAR, N., KUMAR, P., HASSAN, S. M., NARAIN, S. & ROY, R. K. (1998). Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Annals of Tropical Medicine and Parasitology, 92, 561-569.
16. VERWEIJ, J., PLANTING, A., VAN DER BURG, M. & STOTER, G. (1992). A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic tumours. Journal of Cancer Research and Clinical Oncology, 118, 606-608.